Copyright
©The Author(s) 2023.
World J Orthop. Feb 18, 2023; 14(2): 64-82
Published online Feb 18, 2023. doi: 10.5312/wjo.v14.i2.64
Published online Feb 18, 2023. doi: 10.5312/wjo.v14.i2.64
Table 1 Loading factor value
Anti apoptotic | Anti inflammatory | Lokomotorius | Neuroangiogenesis | Neurogenesis | Pro inflammatory | |
Anti apoptotic | 1.000 | |||||
Anti inflammatory 1 | 0.978 | |||||
Anti inflammatory 2 | 0.978 | |||||
Lokomotorius | 1.000 | |||||
Neurogenesis 1 | 0.932 | |||||
Neurogenesis 2 | 0.928 | |||||
Neurogenesis 3 | 0.892 | |||||
Neuroangiogenesi | 1.000 | |||||
Pro inflammatory 1 | 0.940 | |||||
Pro inflammatory 2 | 0.901 | |||||
Pro inflammatory 3 | 0.936 | |||||
Pro inflammatory 4 | 0.770 |
Table 2 Average variance extracted value
Cronbach’s alpha | rho_A | Composite reliability | Average variance extracted | |
Anti apoptotic | 1.000 | 1.000 | 1.000 | 1.000 |
Anti inflammatory | 0.954 | 0.954 | 0.978 | 0.956 |
Lokomotorius | 1.000 | 1.000 | 1.000 | 1.000 |
Neuroangiogenesis | 1.000 | 1.000 | 1.000 | 1.000 |
Neurogenesis | 0.907 | 0.915 | 0.941 | 0.842 |
Pro inflammatory | 0.917 | 0.979 | 0.938 | 0.792 |
Table 3 Discriminant validity values
Anti apoptotic | Anti inflammatory | Lokomotorius | Neuroangiogenesis | Neurogenesis | Pro inflammatory | |
Anti apoptotic | 1.000 | 0.697 | 0.271 | 0.850 | 0.815 | 0.085 |
Anti inflammatory 1 | 0.663 | 0.978 | -0.293 | 0.714 | 0.704 | 0.642 |
Anti inflammatory 2 | 0.699 | 0.978 | -0.140 | 0.796 | 0.739 | 0.532 |
Lokomotorius | 0.271 | -0.220 | 1.000 | 0.064 | 0.072 | -0.869 |
Neurogenesis 1 | 0.725 | 0.691 | -0.037 | 0.961 | 0.932 | 0.369 |
Neurogenesis 2 | 0.776 | 0.612 | 0.313 | 0.862 | 0.928 | -0.006 |
Neurogenesis 3 | 0.748 | 0.736 | -0.084 | 0.804 | 0.892 | 0.338 |
Neuroangiogenesi | 0.850 | 0.772 | 0.064 | 1.000 | 0.958 | 0.319 |
Pro inflammatory 1 | 0.078 | 0.580 | -0.865 | 0.268 | 0.201 | 0.940 |
Pro inflammatory 2 | -0.073 | 0.496 | -0.760 | 0.192 | 0.118 | 0.901 |
Pro inflammatory 3 | 0.257 | 0.654 | -0.740 | 0.455 | 0.392 | 0.936 |
Pro inflammatory 4 | -0.206 | 0.153 | -0.881 | 0.012 | 0.046 | 0.770 |
Table 4 Results of bootstrapping and blindfolding partial least squares structural equation modeling
O | M | STDEV | T statistics (|O/STDEV|) | P values | |
Anti apoptotic - > lokomotorius | 0.109 | 0.129 | 0.210 | 4.519 | 0.000 |
Anti inflammatory - > anti apoptotic | 0.697 | 0.692 | 0.145 | 4.818 | 0.000 |
Anti inflammatory- > neuroangiogenesis | 0.772 | 0.768 | 0.125 | 6.196 | 0.000 |
Neuroangiogenesis - > neurogenesis | 0.176 | 0.183 | 0.258 | 4.682 | 0.000 |
Neurogenesis - > lokomotorius | 0.754 | 0.782 | 0.130 | 5.789 | 0.000 |
Pro inflammatory - > anti inflammatory | 0.600 | 0.622 | 0.193 | 3.102 | 0.002 |
Table 5 F square value
Anti apoptotic | Antiinflammatory | Lokomotorius | Neuroangiogenesis | Neurogenesis | Pro inflammatory | |
Anti apoptotic | 0.197 | |||||
Anti inflammatory | 2.126 | 3.458 | ||||
Lokomotorius | ||||||
Neuroangiogenesis | 0.797 | |||||
Neurogenesis | 0.563 | |||||
Pro inflammatory | 6.163 |
Table 6 Q square value
SSO | SSE | Q² (= 1-SSE/SSO) | |
Anti apoptotic | 15.000 | 8.131 | 0.458 |
Anti inflammatory | 30.000 | 24.178 | 0.194 |
Lokomotorius | 15.000 | 6.222 | 0.585 |
Neuroangiogenesis | 15.000 | 13.410 | 0.106 |
Neurogenesis | 45.000 | 44.724 | 0.006 |
Pro inflammatory | 60.000 | 60.000 |
Table 7 R square value
R square | R square adjusted | |
Anti apoptotic | 0.680 | 0.655 |
Anti inflammatory | 0.860 | 0.850 |
Lokomotorius | 0.536 | 0.459 |
Neuroangiogenesis | 0.776 | 0.758 |
Neurogenesis | 0.444 | 0.401 |
Table 8 Tukey HSD test results of all biomarkers
Biomarker | Group | Group | P value | |
Oxidative stress | F2-Isoprostanes | Treatment (mean = 258.40; SD = 12.45) | Normal (mean = 252.59; SD = 25.54) | 0.938 |
Control (mean = 338.82; SD = 36.87) | 0.001 | |||
Pro-inflammatory | NF-kB | Treatment (mean = 1.400; SD = 0.254) | Normal (mean = 0.475; SD = 0.206) | 0.003 |
Control (mean = 2.820; SD = 0.531) | 0.000 | |||
MMP-9 | Treatment (mean = 1.19; SD = 0.931) | Normal (mean = 0.160; SD = 0.213) | 0.217 | |
Control (mean = 3.09; SD = 1.056) | 0.001 | |||
TNF-α | Treatment (mean = 171.85; SD = 35.84) | Normal (mean = 105.07; SD = 11.34) | 0.002 | |
Control (mean = 215.14; SD = 15.38) | 0.032 | |||
Anti-inflammatory | IL-10 | Treatment (mean = 3.160; SD = 0.801) | Normal (mean = 0.240; SD = 0.167) | 0.000 |
Control (mean = 1.900; SD = 0.734) | 0.022 | |||
TGF-β | Treatment (mean = 2.740; SD = 0.684) | Normal (mean = 0.260; SD = 0.181) | 0.000 | |
Control (mean = 1.840; SD = 0.572) | 0.047 | |||
Neuroangiogenesis | VEGF | Treatment (mean = 5.12; SD = 0.878) | Normal (mean = 0.220; SD = 0.130) | 0.000 |
Control (mean = 2.120; SD = 0.889) | 0.000 | |||
Anti-apoptotic | Bcl-2 | Treatment (mean = 2.02; SD = 0.712) | Normal (mean = 0.160; SD = 0.151) | 0.000 |
Control (mean = 0.500; SD = 0.380) | 0.001 | |||
Neurogenesis | Nestin | Treatment (mean = 1.96; SD = 0.610) | Normal (mean = 0.160; SD = 0.114) | 0.000 |
Control (mean = 1.000; SD = 0.524) | 0.018 | |||
BDNF | Treatment (mean = 2.01; SD = 0.576) | Normal (mean = 0.40; SD = 0.482) | 0.000 | |
Control (mean = 0.57; SD = 0.468) | 0.001 | |||
GDNF | Treatment (mean = 3.420; SD = 2.480) | Normal (mean = 1.420; SD = 0.356) | 0.000 | |
Control (mean = 2.480; SD = 0.788) | 0.043 |
- Citation: Semita IN, Utomo DN, Suroto H. Mechanism of spinal cord injury regeneration and the effect of human neural stem cells-secretome treatment in rat model. World J Orthop 2023; 14(2): 64-82
- URL: https://www.wjgnet.com/2218-5836/full/v14/i2/64.htm
- DOI: https://dx.doi.org/10.5312/wjo.v14.i2.64